세계의 사이키델릭 의약품 시장 보고서(2025년)

Psychedelic drugs constitute a category of psychoactive substances that induce alterations in perception, mood, and thought processes. These substances impact all senses, leading to changes in an individual's thinking, perception of time, and emotions. Examples include chemicals such as Lysergic acid diethylamide (LSD) and plants such as peyote. Psychedelic drugs find applications in the treatment of various mental health conditions.

Psychedelic drugs come in different types, including lysergic acid diethylamide (LSD), ketamine, phencyclidine, gamma-hydroxybutyric acid (GHB), and salvia. LSD, colloquially known as acid, is manufactured in crystalline form and diluted for ingestion. These drugs are used for various disease indications such as depression and PTSD, with applications in treatment-resistant depression, opiate addiction, post-traumatic stress disorder, narcolepsy, and panic disorders. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.

The psychedelic drugs market research report is one of a series of new reports from The Business Research Company that provides psychedelic drugs market statistics, including psychedelic drugs industry global market size, regional shares, competitors with a psychedelic drugs market share, detailed psychedelic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the psychedelic drugs industry. This psychedelic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The psychedelic drugs market size has grown rapidly in recent years. It will grow from $5.56 billion in 2024 to $6.39 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to shifting regulatory landscape, increased mental health awareness, changing public perception.

The psychedelic drugs market size is expected to see rapid growth in the next few years. It will grow to $11.93 billion in 2029 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to advancements in drug development, expansion of therapeutic applications, growing acceptance in medical community, public policy shifts, mental health crisis response. Major trends in the forecast period include focus on education and public awareness, legal and regulatory developments, diversification of psychedelic compounds, patient-centric treatment approaches.

The surge in cases of mental illnesses is anticipated to drive the expansion of the psychedelic drugs market in the future. Mental illnesses encompass health conditions characterized by alterations in emotion, thinking, or behavior, including distress and post-traumatic stress disorder. Psychedelic drugs have demonstrated effectiveness in treating depression and post-traumatic stress disorder, contributing to the reduction of mental illnesses through regular use. For instance, in November 2022, as reported by the UK-based National Centre for Social Research, the percentage of 17- to 19-year-olds with a suspected mental disorder increased from 17.4% in 2021 to 25.7% in 2022. Consequently, the rising number of mental illness cases is a significant driver behind the growth of the psychedelic drugs market.

Government initiatives and programs focused on mental health are expected to drive the growth of the psychedelic drugs market in the future. These initiatives encompass actions, projects, or programs designed by governments to address specific issues, achieve particular goals, or respond to public needs. They facilitate research and clinical trials, which enhance the understanding of the therapeutic potential and safety profiles of psychedelic substances. Furthermore, regulatory reforms or approvals for medical use, prompted by these initiatives, could foster a more favorable environment for the development and commercialization of psychedelic-based treatments. For example, a report published by the National Institute of Mental Health in 2022 revealed that out of 59.3 million adults experiencing any mental illness (AMI), 30 million (50.6%) received mental health treatment in the past year. Thus, government initiatives and programs related to mental health are driving the growth of the psychedelic drugs market.

Major companies in the psychedelic drugs market are concentrating on developing innovative products, such as ketamine, to improve therapeutic outcomes for mental health conditions, enhance patient accessibility to treatment, and investigate new applications for psychedelic compounds in areas like depression, anxiety, PTSD, and substance use disorders. Ketamine is primarily known as an anesthetic and analgesic medication, recognized for its dissociative properties. It is also being investigated for its rapid antidepressant effects in treating severe depression and PTSD. For example, in March 2022, Husch Blackwell, a US-based firm, established the Psychedelics and Emerging Therapies Practice Group. This group aims to support innovators in researching, developing, and commercializing new therapies based on psychedelics. It consists of an interdisciplinary team of lawyers experienced in navigating the complex legal landscape surrounding these substances, which are frequently classified as Schedule I controlled substances under U.S. federal law. This classification creates significant regulatory challenges that can impede research and development efforts.

A notable strategy among major companies in the psychedelic drugs market involves forming partnerships to develop new products and strengthen market positions. Collaborations and partnerships in this sector facilitate the sharing of expertise, resources, and research efforts, expediting the development of innovative treatments and enhancing the understanding of the therapeutic potential of psychedelics. For instance, in March 2022, SciSparc Ltd., an Israel-based biopharmaceutical company, collaborated with Clearmind Medicine Inc., a Canada-based pharmaceutical company. The partnership focuses on exploring the development of innovative compounds in the psychedelic field, aiming to create drug candidates with robust efficacy and safety profiles for treating mental health-related diseases. The collaboration includes joint pre-clinical studies, and both companies anticipate that positive results could deepen their partnership in the pursuit of novel psychedelic-derived therapeutics. This strategic alliance reflects the growing interest and investment in the psychedelic pharmaceutical sector, driven by the potential for groundbreaking treatments and addressing underserved health problems.

In April 2022, Numinus, a Canada-based company specializing in psychedelic medicine with integrated psychotherapy, acquired Novamind for $20.77 million. This acquisition positions Numinus to expand its psychotherapy clinics in the US and advance psychedelic programs. Novamind, a US-based mental health company and psychedelic medicine manufacturer, contributes to Numinus's strategic growth in the evolving landscape of psychedelic treatments.

Major companies operating in the psychedelic drugs market include Atai Life Sciences, Cybin Inc., Mind Medicine Inc., Compass Pathways, Seelos Therapeutics, Numinus Wellness Inc., GH Research, Revive Therapeutics, Havn Life Sciences, PharmaTher Holdings, Field Trip Health, Small Pharma, Incannex Healthcare, Optimi Health, NeonMind Biosciences, Entheon Biomedical, Mydecine Innovations Group, Red Light Holland, Eleusis, MAPS Public Benefit Corporation, Beckley Psytech, Awakn Life Sciences, Psygen Industries, Enveric Biosciences, Filament Health, Tactogen, Bexson Biomedical, BetterLife Pharma, Clairvoyant Therapeutics, Universal Ibogaine

North America was the largest region in the psychedelic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychedelic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the psychedelic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The psychedelic drugs market consists of sales of psilocybin, PCP, cannabis, and ecstasy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Psychedelic Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on psychedelic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for psychedelic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The psychedelic drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Lysergic Acid Diethylamide (LSD); Ketamine; Phencyclidine; Gamma Hydroxybutyric Acid (GHB); Salvia
• 2) By Disease Indication: Depression; PTSD
• 3) By Origin: Natural; Synthetic
• 4) By Application: Treatment-Resistant Depression; Opiate addiction; Post- Traumatic Stress Disorder; Narcolepsy; Panic Disorders
• 5) By Distribution Channel: Hospitals Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Lysergic Acid Diethylamide (LSD): LSD Tablets; LSD Liquid; LSD Blotters
• 2) By Ketamine: Ketamine Infusion; Ketamine Nasal Spray; Ketamine Injectable
• 3) By Phencyclidine (PCP): PCP Powder; PCP Tablets; PCP Liquid
• 4) By Gamma Hydroxybutyric Acid (GHB): GHB Liquid; GHB Powder; GHB Capsules
• 5) By Salvia: Salvia Extract; Salvia Dried Leaves; Salvia Tinctures
• Companies Mentioned: Atai Life Sciences; Cybin Inc.; Mind Medicine Inc.; Compass Pathways; Seelos Therapeutics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Psychedelic Drugs Market Characteristics

3. Psychedelic Drugs Market Trends And Strategies

4. Psychedelic Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Psychedelic Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Psychedelic Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Psychedelic Drugs Market Growth Rate Analysis
• 5.4. Global Psychedelic Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Psychedelic Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Psychedelic Drugs Total Addressable Market (TAM)

6. Psychedelic Drugs Market Segmentation

• 6.1. Global Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lysergic Acid Diethylamide (LSD)
• Ketamine
• Phencyclidine
• Gamma Hydroxybutyric Acid (GHB)
• Salvia
• 6.2. Global Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Depression
• PTSD
• 6.3. Global Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Natural
• Synthetic
• 6.4. Global Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Treatment-Resistant Depression
• Opiate addiction
• Post-Traumatic Stress Disorder
• Narcolepsy
• Panic Disorders
• 6.5. Global Psychedelic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.6. Global Psychedelic Drugs Market, Sub-Segmentation Of Lysergic Acid Diethylamide (LSD), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• LSD Tablets
• LSD Liquid
• LSD Blotters
• 6.7. Global Psychedelic Drugs Market, Sub-Segmentation Of Ketamine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ketamine Infusion
• Ketamine Nasal Spray
• Ketamine Injectable
• 6.8. Global Psychedelic Drugs Market, Sub-Segmentation Of Phencyclidine (PCP), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PCP Powder
• PCP Tablets
• PCP Liquid
• 6.9. Global Psychedelic Drugs Market, Sub-Segmentation Of Gamma Hydroxybutyric Acid (GHB), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• GHB Liquid
• GHB Powder
• GHB Capsules
• 6.10. Global Psychedelic Drugs Market, Sub-Segmentation Of Salvia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Salvia Extract
• Salvia Dried Leaves
• Salvia Tinctures

7. Psychedelic Drugs Market Regional And Country Analysis

• 7.1. Global Psychedelic Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Psychedelic Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Psychedelic Drugs Market

• 8.1. Asia-Pacific Psychedelic Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Psychedelic Drugs Market

• 9.1. China Psychedelic Drugs Market Overview
• 9.2. China Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Psychedelic Drugs Market

• 10.1. India Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Psychedelic Drugs Market

• 11.1. Japan Psychedelic Drugs Market Overview
• 11.2. Japan Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Psychedelic Drugs Market

• 12.1. Australia Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Psychedelic Drugs Market

• 13.1. Indonesia Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Psychedelic Drugs Market

• 14.1. South Korea Psychedelic Drugs Market Overview
• 14.2. South Korea Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Psychedelic Drugs Market

• 15.1. Western Europe Psychedelic Drugs Market Overview
• 15.2. Western Europe Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Psychedelic Drugs Market

• 16.1. UK Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Psychedelic Drugs Market

• 17.1. Germany Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Psychedelic Drugs Market

• 18.1. France Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Psychedelic Drugs Market

• 19.1. Italy Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Psychedelic Drugs Market

• 20.1. Spain Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Psychedelic Drugs Market

• 21.1. Eastern Europe Psychedelic Drugs Market Overview
• 21.2. Eastern Europe Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Psychedelic Drugs Market

• 22.1. Russia Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Psychedelic Drugs Market

• 23.1. North America Psychedelic Drugs Market Overview
• 23.2. North America Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Psychedelic Drugs Market

• 24.1. USA Psychedelic Drugs Market Overview
• 24.2. USA Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Psychedelic Drugs Market

• 25.1. Canada Psychedelic Drugs Market Overview
• 25.2. Canada Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Psychedelic Drugs Market

• 26.1. South America Psychedelic Drugs Market Overview
• 26.2. South America Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Psychedelic Drugs Market

• 27.1. Brazil Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Psychedelic Drugs Market

• 28.1. Middle East Psychedelic Drugs Market Overview
• 28.2. Middle East Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Psychedelic Drugs Market

• 29.1. Africa Psychedelic Drugs Market Overview
• 29.2. Africa Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Psychedelic Drugs Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Psychedelic Drugs Market, Segmentation By Origin, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Psychedelic Drugs Market Competitive Landscape And Company Profiles

• 30.1. Psychedelic Drugs Market Competitive Landscape
• 30.2. Psychedelic Drugs Market Company Profiles
  • 30.2.1. Atai Life Sciences Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Cybin Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Mind Medicine Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Compass Pathways Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Seelos Therapeutics Overview, Products and Services, Strategy and Financial Analysis

31. Psychedelic Drugs Market Other Major And Innovative Companies

• 31.1. Numinus Wellness Inc.
• 31.2. GH Research
• 31.3. Revive Therapeutics
• 31.4. Havn Life Sciences
• 31.5. PharmaTher Holdings
• 31.6. Field Trip Health
• 31.7. Small Pharma
• 31.8. Incannex Healthcare
• 31.9. Optimi Health
• 31.10. NeonMind Biosciences
• 31.11. Entheon Biomedical
• 31.12. Mydecine Innovations Group
• 31.13. Red Light Holland
• 31.14. Eleusis
• 31.15. MAPS Public Benefit Corporation

32. Global Psychedelic Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Psychedelic Drugs Market

34. Recent Developments In The Psychedelic Drugs Market

35. Psychedelic Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Psychedelic Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Psychedelic Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Psychedelic Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer